Phase 3 N=151 Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.
Infertility
Primary: Total Number of Oocytes Retrieved — 10.9; 12.0 oocytes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=870 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
Chronic Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Study Drug (SVR12) — 98.6; 97.2; 98.2; 99.1 percentage of…
Phase 3 N=27 Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles
Oocyte Donation
Primary: Number of Patients Producing Anti-FSH Antibodies. — 0 participants
Phase 3 N=325 Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
Schizophrenia
Primary: Number of Inpatient Psychiatric Hospitalization for Retrospective Period (Months 4-6) and Prospective Period (Months 4-6). — 91; 9 participants — p=<.0001
Phase 3 N=565 A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 9.17; 7.62 months — p=0.1391
Phase 3 N=835 Virtual Continuity and Its Impact on Complex Hospitalized Patients' Care
Automated Communication Tools · Complex Medical Patients
Primary: Medication Errors at Hospital Discharge — 645; 359 Errors
Phase 3 N=218 Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
Alzheimer Disease
Primary: Sensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral…
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
Phase 3 N=21,105 Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
Stroke · Atrial Fibrillation · Embolism
Primary: Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE). — 253; 182; 232 number of participants with event — p=<.0001
Phase 3 N=153 Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 97.8; 95.2 percentage of participants
Phase 3 N=616 Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
Persistent Allergic Asthma
Primary: Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Following the 24-week Treatment Period — 27.03; 18.18 L/min
Phase 3 N=59 Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core — 27; 29; 3; 3 participants
Phase 3 N=50 Safety and Efficacy of Adjustable Gastric Band Operations for Patients With Body Mass Index (BMI) Between 30-40 kg/m2
Obesity
Primary: To Determine Percent of Excess Weight Loss (%EWL) After Laparoscopic Adjustable Gastric Banding Surgery — 51.74 percentage of excess weight loss
Phase 3 N=323 Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
Neovascular Age-related Macular Degeneration
Primary: Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD — 290; 239; 204; 169 participants
Phase 3 N=326 Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children
Acute Otitis Media
Primary: Effectiveness of Viscous-adherent Xylitol Syrup in Reducing Episodes of Clinically-diagnosed Acute Otitis Media — 66.9; 63.3 percentage of particpants — p=0.6